Ventyx Biosciences Stock Analysis
| VTYX Stock | USD 3.03 0.08 2.71% |
Ventyx Biosciences is undervalued with Real Value of 5.13 and Target Price of 12.0. The main objective of Ventyx Biosciences stock analysis is to determine its intrinsic value, which is an estimate of what Ventyx Biosciences is worth, separate from its market price. There are two main types of Ventyx Biosciences' stock analysis: fundamental analysis and technical analysis.
The Ventyx Biosciences stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Ventyx Biosciences is usually not traded on Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day. Ventyx Stock trading window is adjusted to America/New York timezone.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Ventyx Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. Ventyx Stock Analysis Notes
About 74.0% of the company outstanding shares are owned by institutional investors. The company has Price to Book (P/B) ratio of 0.97. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. Ventyx Biosciences recorded a loss per share of 1.74. The entity had not issued any dividends in recent years. Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California. Ventyx Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 34 people. For more information please call Raju Mohan at 760 593 4832 or visit https://ventyxbio.com.Ventyx Biosciences Investment Alerts
| Ventyx Biosciences is way too risky over 90 days horizon | |
| Ventyx Biosciences appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (135.12 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Ventyx Biosciences currently holds about 250.45 M in cash with (130.87 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.92, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Ventyx Biosciences has a frail financial position based on the latest SEC disclosures | |
| Roughly 74.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Disposition of 1651 shares by Krueger Christopher W of Ventyx Biosciences at 5.4036 subject to Rule 16b-3 |
Ventyx Biosciences Upcoming and Recent Events
Earnings reports are used by Ventyx Biosciences to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period..
| 28th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 28th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Ventyx Largest EPS Surprises
Earnings surprises can significantly impact Ventyx Biosciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2022-08-15 | 2022-06-30 | -0.45 | -0.39 | 0.06 | 13 | ||
2024-05-09 | 2024-03-31 | -0.69 | -0.62 | 0.07 | 10 | ||
2022-05-12 | 2022-03-31 | -0.52 | -0.45 | 0.07 | 13 |
Ventyx Biosciences Environmental, Social, and Governance (ESG) Scores
Ventyx Biosciences' ESG score is a quantitative measure that evaluates Ventyx Biosciences' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Ventyx Biosciences' operations that may have significant financial implications and affect Ventyx Biosciences' stock price as well as guide investors towards more socially responsible investments.
Ventyx Stock Institutional Investors
| Shares | Monaco Asset Management | 2025-03-31 | 1.1 M | Jpmorgan Chase & Co | 2025-03-31 | 1 M | Bank Of America Corp | 2025-03-31 | 1 M | Renaissance Technologies Corp | 2025-03-31 | 1 M | Sphera Funds Management Ltd. | 2025-03-31 | 1 M | Aqr Capital Management Llc | 2025-03-31 | 880.2 K | Morgan Stanley - Brokerage Accounts | 2025-03-31 | 876.2 K | Connor Clark & Lunn Inv Mgmt Ltd | 2025-03-31 | 871.6 K | Goldman Sachs Group Inc | 2025-03-31 | 593.2 K | Blackrock Inc | 2025-03-31 | 4.4 M | Point72 Asset Management, L.p. | 2025-03-31 | 4.2 M |
Ventyx Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 225.23 M.Ventyx Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.49) | (0.51) | |
| Return On Capital Employed | (0.56) | (0.53) | |
| Return On Assets | (0.49) | (0.51) | |
| Return On Equity | (0.53) | (0.51) |
Management Efficiency
Ventyx Biosciences has return on total asset (ROA) of (0.292) % which means that it has lost $0.292 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4604) %, meaning that it created substantial loss on money invested by shareholders. Ventyx Biosciences' management efficiency ratios could be used to measure how well Ventyx Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.51 in 2025. Return On Capital Employed is likely to rise to -0.53 in 2025. Net Tangible Assets is likely to rise to about 427.3 M in 2025, whereas Total Assets are likely to drop slightly above 223.3 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 3.71 | 2.59 | |
| Tangible Book Value Per Share | 3.71 | 2.59 | |
| Enterprise Value Over EBITDA | (1.00) | (1.05) | |
| Price Book Value Ratio | 0.59 | 0.62 | |
| Enterprise Value Multiple | (1.00) | (1.05) | |
| Price Fair Value | 0.59 | 0.62 | |
| Enterprise Value | 153.5 M | 145.9 M |
The strategic vision of Ventyx Biosciences management plays a critical role in its financial performance. By evaluating this vision, we provide insights into the stock's growth potential.
Technical Drivers
As of the 22nd of July, Ventyx Biosciences has the Coefficient Of Variation of 400.35, risk adjusted performance of 0.2414, and Semi Deviation of 4.9. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Ventyx Biosciences, as well as the relationship between them.Ventyx Biosciences Price Movement Analysis
The output start index for this execution was twenty-nine with a total number of output elements of thirty-two. The Simple Moving Average indicator is calculated by adding the closing price of Ventyx Biosciences for a given number of time periods and then dividing this total by the number of time periods. It is used to smooth out Ventyx Biosciences short-term fluctuations and highlight longer-term trends or cycles.
Ventyx Biosciences Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Ventyx Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Ventyx Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Ventyx Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Ventyx Biosciences Outstanding Bonds
Ventyx Biosciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Ventyx Biosciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Ventyx bonds can be classified according to their maturity, which is the date when Ventyx Biosciences has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
Ventyx Biosciences Predictive Daily Indicators
Ventyx Biosciences intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Ventyx Biosciences stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Ventyx Biosciences Forecast Models
Ventyx Biosciences' time-series forecasting models are one of many Ventyx Biosciences' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Ventyx Biosciences' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Ventyx Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Ventyx Biosciences prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Ventyx shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Ventyx Biosciences. By using and applying Ventyx Stock analysis, traders can create a robust methodology for identifying Ventyx entry and exit points for their positions.
| Last Reported | Projected for Next Year |
Current Ventyx Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Ventyx analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Ventyx analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 12.0 | Strong Buy | 9 | Odds |
Most Ventyx analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Ventyx stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Ventyx Biosciences, talking to its executives and customers, or listening to Ventyx conference calls.
Ventyx Stock Analysis Indicators
Ventyx Biosciences stock analysis indicators help investors evaluate how Ventyx Biosciences stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Ventyx Biosciences shares will generate the highest return on investment. By understating and applying Ventyx Biosciences stock analysis, traders can identify Ventyx Biosciences position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 52.6 M | |
| Common Stock Shares Outstanding | 68.5 M | |
| Total Stockholder Equity | 254 M | |
| Total Cashflows From Investing Activities | -15.5 M | |
| Property Plant And Equipment Net | 10.3 M | |
| Cash And Short Term Investments | 217.3 M | |
| Cash | 27.3 M | |
| Accounts Payable | 3.1 M | |
| Net Debt | -16.5 M | |
| 50 Day M A | 2.111 | |
| Total Current Liabilities | 12.8 M | |
| Non Current Assets Total | 46.9 M | |
| Non Currrent Assets Other | 1 M | |
| Stock Based Compensation | 22.9 M |
Additional Tools for Ventyx Stock Analysis
When running Ventyx Biosciences' price analysis, check to measure Ventyx Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ventyx Biosciences is operating at the current time. Most of Ventyx Biosciences' value examination focuses on studying past and present price action to predict the probability of Ventyx Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ventyx Biosciences' price. Additionally, you may evaluate how the addition of Ventyx Biosciences to your portfolios can decrease your overall portfolio volatility.